Amneal Launches FDA-Approved Lanreotide, Targeting a $983 Million Reference Market
Market Chameleon (Mon, 21-Sep 7:15 AM ET)
Amneal Announces FDA Approval and Launch of Lanreotide Injection
Globe Newswire (Fri, 18-Sep 4:01 PM ET)
Business Wire (Wed, 19-Aug 8:00 AM ET)
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
Amneal Reports Second Quarter 2026 Financial Results
Globe Newswire (Thu, 30-Jul 6:00 AM ET)
Business Wire (Thu, 23-Jul 1:27 PM ET)
Globe Newswire (Fri, 17-Jul 8:00 AM ET)
Amneal to Report Second Quarter 2026 Results on July 30, 2026
Globe Newswire (Thu, 9-Jul 4:05 PM ET)
Amneal Exceeds 2025 Guidance and Eyes More Growth for 2026 as Portfolio Strengthens
Market Chameleon (Fri, 27-Feb 4:21 AM ET)
Amneal Targets Major Growth with Early Biosimilar Submission for $4.1B XOLAIR Market
Market Chameleon (Fri, 26-Sep 5:46 AM ET)
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Amneal Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol AMRX.
As of October 5, 2026, AMRX stock price climbed to $20.42 with 1,502,644 million shares trading.
AMRX has a beta of 0.70, meaning it tends to be less sensitive to market movements. AMRX has a correlation of 0.06 to the broad based SPY ETF.
AMRX has a market cap of $7.11 billion. This is considered a Mid Cap stock.
Last quarter Amneal Pharmaceuticals - Class A reported $796 million in Revenue and $.30 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.07.
In the last 3 years, AMRX traded as high as $21.18 and as low as $3.36.
The top ETF exchange traded funds that AMRX belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
AMRX has outperformed the market in the last year with a price return of +96.3% while the SPY ETF gained +17.0%. AMRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.1% and +9.1%, respectively, while the SPY returned +4.3% and +1.8%, respectively.
AMRX support price is $19.69 and resistance is $20.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMRX shares will trade within this expected range on the day.
